Stock Ratings / Health Care / OABI / earnings

NRC (65) ABSI (45) MXCT (30) ICLR (71) ⌘ Pro Terminal →

OmniAb Inc. (OABI) Next Earnings Date & Expected ±12.5% Move

$5.23 -0.95% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

OmniAb Inc. (OABI) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $760.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OABI)Realized 20D OHLCV Swing Band: ±12.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.65 Expected Swing

MODEL EARNINGS SETUP GAUGE

OABI Quantitative Pre-Earnings Setup: 38/100

Trailing EPS: $4.25 • YoY Revenue Growth: -29.3%

Model Bullish Setup (38/100)Model Risk Weight (62/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$18.7M	-$64.8M	-$37.0M	52%
FY 2024	2024-12-31	$26.4M	-$62.0M	-$41.5M	52%
FY 2023	2023-12-31	$34.2M	-$50.6M	$2.3M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OABI)

✓Walkthrough of OABI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

OABI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +276.26%▲ ASCENDING CHANNEL

2026-10-30O $4.40H $5.23L $4.35C $5.23VOL 2.11M

RES: $7.10SUP: $2.50SMA50: $4.65SMA200: $2.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OABI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OABI Butterfly Map → + Track OABI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -29.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OABI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OABI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for OABI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OABI)

Health Care Rank #703 of 1016 ⚔️ NRC vs OABI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OABI vs. NRC, ABSI, MXCT, ICLR)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, OmniAb Inc. (OABI) ranks #703 by composite RQD confidence (38/100, grade D-) and #392 by equity capitalization ($760.4M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. ICLR currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with OABI at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
OABI ACTIVE OmniAb Inc.	D-	38/100	—	—	-22.6%	-0.95%	$760.4M	Benchmark Subject
NRC NRC Health	C	65/100	44.8x	—	21.0%	+0.09%	$519.6M	/nrc-vs-oabi →
ABSI Absci Corporation	D	45/100	—	—	-35.0%	+1.85%	$2.08B	/absi-vs-oabi →
MXCT MaxCyte Inc.	E	30/100	—	96.0%	-27.1%	+1.17%	$178.5M	/mxct-vs-oabi →
ICLR ICON plc	B-	71/100	71.9x	—	3.1%	+0.62%	$16.50B	/iclr-vs-oabi →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001846253

In its most recent audited fiscal period (FY2025, filed 2025-12-31), OmniAb Inc. (OABI) reported GAAP revenue of $18.7M (-29.3% vs. FY2024 revenue of $26.4M , and -45.4% cumulative change since FY2023) , GAAP net income of -$64.8M, operating cash flow of -$36.5M, and free cash flow of -$37.0M (+10.9% YoY). On the balance sheet, OABI closed FY2025 with $300.9M in total assets against $0 in total debt (Altman Z-Score: 12.19, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$18.7M	-$64.8M	-$36.5M	-$37.0M	$300.9M	—
FY2024 (FY)	2024-12-31	$26.4M	-$62.0M	-$39.7M	-$41.5M	$325.6M	—
FY2023 (FY)	2023-12-31	$34.2M	-$50.6M	$2.3M	$2.3M	—	—

3. OABI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OABI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, OmniAb Inc. (NASDAQ: OABI) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $5.23 (-0.95% 1D, market cap $760.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OABI ranks #703 in composite RQD confidence.

How does OABI compare to NRC and ABSI in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), OABI carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.6%. By comparison, NRC (NRC Health) holds a C grade (65/100 RQD, P/E 44.8x, ROIC 21.0%, cap $519.6M) and ABSI (Absci Corporation) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.08B). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OABI?

Per OABI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001846253), OmniAb Inc. generated $18.7M in revenue (-29.3% YoY), -$64.8M in net income, and -$37.0M in free cash flow against $300.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OABI trading relative to its 50-day, 200-day, and 52-week technical levels?

OABI last traded at $5.23 (-0.95% on volume of 1,683,619 shares), positioning the stock +12.47% above its 50-day simple moving average ($4.65) and +93.70% above its 200-day simple moving average ($2.70). Across its 52-week range of $1.30 to $5.43, OABI sits at the 95.2% percentile with a 14-day RSI of 58.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.58 to $5.88).